白细胞介素23抑制剂治疗对银屑病共病的影响  

Effects of interleukin-23 inhibitors on psoriasis comorbidities

作　　者：李秀珍 徐秀莲 Li Xiuzhen;Xu Xiulian(Department of Pathology,Hospital of Dermatology,Chinese Academy of Medical Sciences and Peking Union Medical College,Nanjing 210042,China)

机构地区：[1]中国医学科学院、北京协和医学院皮肤病医院病理科,南京210042

出　　处：《中华皮肤科杂志》2025年第3期268-272,共5页Chinese Journal of Dermatology

摘　　要：近年来,生物制剂在银屑病治疗中占据了重要地位。其中,白细胞介素23(IL-23)抑制剂显示出较高的有效性和安全性。同时,IL-23抑制剂治疗还对诸如银屑病关节炎、心血管疾病、代谢综合征、炎症性肠病等银屑病共病的发生、发展产生重要影响。本文从IL-23/IL-17通路参与各类银屑病共病的发病机制入手,结合相关临床试验、病例报道及国内外诊疗指南推荐,就IL-23抑制剂治疗对银屑病共病的影响进行综述,为伴不同共病的银屑病患者选择合适的治疗方案提供参考。In recent years,biological agents have played an important role in the treatment of psoriasis,among which interleukin(IL)-23 inhibitors have shown favorable efficacy and safety.In addition,IL-23 inhibitors can influence the onset and development of psoriasis comorbidities,such as psoriatic arthritis,cardiovascular diseases,metabolic syndrome,and inflammatory bowel disease.This review first discusses the involvement of the IL-23/IL-17 pathway in the pathogenesis of various psoriasis comorbidities,and then summarizes the effects of IL-23 inhibitors on psoriasis comorbidities based on clinical trials,case reports,and Chinese and international guidelines,aiming to provide a reference for choosing appropriate treatments for psoriasis patients with different comorbidities.

关 键 词：银屑病 共病现象 关节炎 牛皮癣 炎性肠疾病 心血管不良事件 恶性肿瘤 白细胞介素23抑制剂 

分 类 号：R75[医药卫生—皮肤病学与性病学]